DEBBIE MARSHALL: Open Payments
NPI 1639315831 · MANSFIELD, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,843 in 96 payments from 12 companies in 2025. Trend: 2023 $50 · 2024 $274 · 2025 $1,843
Food & beverage: $1,744Education: $99
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $212 |
| Lundbeck LLC | 9 | $209 |
| Teva Pharmaceuticals USA, Inc. | 7 | $190 |
| Neurocrine BioSciences, Inc. | 10 | $186 |
| Otsuka America Pharmaceutical, Inc. | 9 | $180 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $178 |
| E.R. Squibb & Sons, L.L.C. | 12 | $149 |
| Vanda Pharmaceuticals Inc. | 7 | $149 |
| ABBVIE INC. | 7 | $144 |
| Luye Pharma (USA) Ltd. | 5 | $111 |
Products named: ABILIFY MAINTENA, ARISTADA, INGREZZA, CAPLYTA, COBENFY, FANAPT, VRAYLAR, ERZOFRI EXTENDED-RELEASE.
Industry payments across OH — which companies pay providers there.
